December 04, 2016 11:39 AM ET


Company Overview of Cocrystal Pharma, Inc.

Company Overview

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus (HCV), Influenza virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepatitis C viral replication. The co...

1860 Montreal Road

Tucker, GA 30084

United States

Founded in 2007

23 Employees





Key Executives for Cocrystal Pharma, Inc.

Co-Founder, Vice Chairman and Interim Chief Executive Officer
Age: 69
Total Annual Compensation: $133.5K
Co-Founder and President
Age: 56
Total Annual Compensation: $203.6K
Interim Chief Financial Officer and Controller
Age: 59
Total Annual Compensation: $58.7K
General Counsel and Corporate Secretary
Age: 55
Total Annual Compensation: $132.8K
Compensation as of Fiscal Year 2015.

Cocrystal Pharma, Inc. Key Developments

Cocrystal Pharma, Inc. Announces Positive Interim Data from an Ongoing Phase 1 Study with CC-31244 for the Treatment of Chronic Hepatitis C Infection

Cocrystal Pharma, Inc. announced positive data from a randomized, double-blind Phase Ia/Ib study of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor (NNI), for the treatment of chronic hepatitis C virus (HCV) infection. The study is designed to evaluate CC-31244's safety/tolerability and pharmacokinetics, including food effect and antiviral activity. The study includes two groups: Group A (single ascending doses, and multiple doses in healthy volunteers), and Group B (multiple doses in HCV infected individuals). The study has dosed a total of 42 healthy volunteers with single (20, 50, 100, 200 and 400 mg) and multiple doses of CC-31244 at 200 and 400 mg for 7 days. Five HCV GT1 infected patients were dosed, four with 400 mg of CC-31244 once daily for 7 days and one with placebo. Data from the once daily 400 mg dosing arm demonstrate that CC-31244 had a substantial and durable antiviral effect with an average HCV RNA viral load decline from baseline of 3 log orders by 48 hours after dosing. The average viral load at 6 days post last dose remained on average 1.9 log orders below baseline. In addition, no viral breakthrough was observed during the treatment period. No serious adverse event was reported. CC-31244 is an investigational, oral, potent, pan-genotypic NNI with high barrier to drug resistance designed and developed using the company's proprietary structure-based drug discovery technology. The molecule interacts with the NS5B RNA polymerase of all major HCV genotypes.

Cocrystal Pharma, Inc. Presents at Ladenburg Thalmann 2nd Annual Healthcare Conference, Sep-27-2016 12:00 PM

Cocrystal Pharma, Inc. Presents at Ladenburg Thalmann 2nd Annual Healthcare Conference, Sep-27-2016 12:00 PM. Venue: The Sofitel New York, New York, New York, United States. Speakers: Gary L. Wilcox, Co-Founder, Vice Chairman, Interim Chief Executive Officer and Member of Scientific Review Committee.

Cocrystal Pharma, Inc. Announces Management Changes

Cocrystal Pharma, Inc. announced that Dr. Gary Wilcox will assume the role of interim Chief Executive Officer effective July 22, 2016. Dr. Wilcox previously served as the Chief Executive Officer of Cocrystal from 2008 to 2015. Mr. Jeffrey Meckler stepped down as Chief Executive Officer and from the Board to pursue other interests. Dr. Wilcox will continue to serve as the Vice Chairman of the Board of Directors of the company. In addition, Dr. Douglas Mayers, the Chief Medical Officer at Cocrystal, submitted his resignation effective immediately. Dr. Luz Pascual, Vice President Clinical Development, shall continue to oversee the ongoing clinical programs. Dr. Wilcox has over 35 years of experience in biotech companies including 14 years at Icos Corporation where he played a key role in the development of Cialis as the Executive Vice President of Operations and a member of the board of directors.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Private Placement
September 1, 2016
Private Placement
August 17, 2016
Private Placement
March 14, 2016

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Cocrystal Pharma, Inc., please visit Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at